Trastuzumab deruxtecan: all 123 studies that test it
Page 2 of 2. Open to participants first (76), then studies with results posted, then the rest; newest registration first within each.
- Study of DS-8201a in Subjects With Advanced Solid Malignant TumorsCompletedNCT02564900Phase 1Results posted
- Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction AdenocarcinomaCompletedNCT07529613Phase 1/2
- A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung CancerWithdrawnNCT07428044Phase 2
- A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast CancerWithdrawnNCT06585969Phase 3
- Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian PatientsActive, not recruitingNCT06429761Phase 4
- A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid TumorsActive, not recruitingNCT06244485Phase 1
- PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerActive, not recruitingNCT06172127Phase 2
- T-DXd Therapy for HER2-low Breast Cancer Patients With Brain MetastasesActive, not recruitingNCT06048718Phase 2
- Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)Active, not recruitingNCT05710666Phase 2
- Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast CancerActive, not recruitingNCT05633979Phase 1
- Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal JunctionActive, not recruitingNCT05480384Phase 2
- StrataPATH™ (Precision Indications for Approved Therapies)TerminatedNCT05097599Phase 2
- A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 MutationsActive, not recruitingNCT05048797Phase 3
- Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Active, not recruitingNCT04784715Phase 3
- Phase II Study of T-DX in HER2-positive Breast Cancer Brain MetastasesCompletedNCT04752059Phase 2
- Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Active, not recruitingNCT04704934Phase 3
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingNCT04704661Phase 1
- A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)Active, not recruitingNCT04622319Phase 3
- A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing TumorsActive, not recruitingNCT04482309Phase 2
- Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)Active, not recruitingNCT04379596Phase 2
- Testing the Biological Effects of DS-8201a on Patients With Advanced CancerActive, not recruitingNCT04294628Phase 1
- Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers AnalysisCompletedNCT04132960Phase 2
- DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerActive, not recruitingNCT04042701Phase 1